BC
TGTX icon

Burney Company’s TG Therapeutics TGTX Stock Holding History

Burney Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,991
Closed -$477K – 649
2025
Q4 		$477K Hold
15,991
– – 0.01% 440
2025
Q3 		$578K Sell
15,991
-26,985
-63% -$889K 0.02% 398
2025
Q2 		$1.55M Sell
42,976
-1,050
-2% -$39.1K 0.05% 260
2025
Q1 		$1.74M Sell
44,026
-859
-2% -$28.9K 0.06% 228
2024
Q4 		$1.35M Sell
44,885
-415
-0.9% -$11.9K 0.05% 271
2024
Q3 		$1.06M Buy
45,300
+302
+0.7% +$6.6K 0.04% 311
2024
Q2 		$801K Buy
+44,998
New +$718K 0.03% 351

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Burney Company's TGTX Position: Q1 2026 in Review

Burney Company sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 15,991 shares — an estimated $477K sold.

Burney Company first reported a position in TGTX in Q2 2024 and held it in 7 quarters. The position peaked at $1.74M in Q1 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Burney Company reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Burney Company sold 15,991 TG Therapeutics shares in Q1 2026, an estimated $477K.
  • Burney Company first reported a position in TG Therapeutics in Q2 2024 and held it in 7 quarters.
  • Burney Company's TG Therapeutics position peaked at $1.74M in Q1 2025.
  • 364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Burney Company's 13F filing for Q1 2026, filed 29 Apr 2026.